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ABSTRACT
Objective: This study was planned to analyze the prescription patterns and compare the cost of antidiabetic drugs in our tertiary care teaching 
hospital.
Methods: It was a prospective observational study conducted over a period of 6-month. Data were collected on a predesigned case record form from 
patients of diabetes attending medicine outpatient department, and the core prescribing indicators were evaluated. Their pharmacy bill was also 
collected and analyzed and percentage variation in the cost of antidiabetic drugs was calculated.
Results: A total of 262 prescriptions were analyzed showing the main age group between 50 and 60 years (39.69%). Out of 262 patients, 141 (53.82%) 
were males and 121 (46.18%) were females. 176 (67.17%) prescriptions had 2-5 drugs showing clear evidence of polypharmacy. The total number 
of drugs prescribed in 262 prescriptions were 1209, and thus, an average number of drugs prescribed were 4.61/prescription. The most common 
antidiabetic drug prescribed was metformin 500 mg in 189 (33.99%) patients, and the most common antidiabetic combination was glimepiride 2 mg 
+ metformin 500 mg in 62 (34.63%) patients. Insulin was used in 37 (14.12%) prescriptions. Among other drugs, maximally used were atorvastatin 
86 (7.11%) followed by aspirin 54 (4.46%) patients. The percentage cost difference of antidiabetic drugs varies from 40.62 to 633.33. The cost of 
monthly therapy for a maximum number of patients was in the cost range INR 100-500 in 148 (56.48%) patients.
Conclusion: The most frequently prescribed antidiabetic drug was metformin and the most frequently used combination used was glimepiride and 
metformin. Polypharmacy was also evident in our study, and the cost of monthly antidiabetic therapy was also moderately high.
Keywords: Pharmacoeconomic, Drug utilization, Antidiabetic drugs.
INTRODUCTION
Diabetes is a group of metabolic disorders characterized by chronic 
hyperglycemia along with disturbance of carbohydrate, protein, and 
fat metabolism due to defects in insulin secretion and/or insulin 
response [1]. It is a chronic disorder requiring life-long treatment to 
maintain the blood glucose levels which if not controlled may lead to 
numerous complications, which degrades the quality of life.
Approximately 381 million people worldwide had diabetes according to 
International Diabetes Federation 2013 report. Its incidence is growing 
rapidly, and by 2030, this number is expected to be double [2]. As stated 
by the Indian Heart Association, India is the diabetes capital of the world 
with an estimated 109 million individuals with diabetes by 2035 [3]. 
This high incidence of diabetes in a developing country like India may 
be due to urbanization and lifestyle changes like consumption of high-
calorie food along with sedentary habits in predisposed individuals 
who are genetically susceptible.
Diabetes has major social and economic implications; hence, the cost of 
antidiabetic therapy is one of the main factors for patient compliance.
Diabetes mainly occurs in older age group, though incidence is now 
increasing in younger population. The geriatric population has special 
problems related to health, economic and social support [4]. Elderly 
diabetic patients usually suffer from comorbidities which necessitate 
the use of numerous medications. Moreover, elderly people show 
physiological variations which may lead to pharmacokinetic and 
pharmacodynamic variations/interactions among drugs used. Thus, 
improper medication use, irrational prescribing, occurrence of adverse 
drug reactions (ADRs) and non-compliance due to economic and health 
issues are common in elderly. Hence, we specifically need to address 
these issues and formulate strategies for geriatric prescribing.
Rational prescribing indicates that “patients receive medications 
appropriate to their clinical needs, in doses that meet their own 
individual requirements, for an adequate period, and at the lowest cost 
to them and their community” [5]. It is demonstrated by drug utilization 
studies. Drug utilization as defined by WHO is, prescribing, dispensing, 
ingesting, marketing, distribution and use of drugs in society, with 
special emphasis on the resulting medical, social and economic 
consequences. These studies are important as they help to scrutinize 
newer drugs in the market, analyze the wide variation in the patterns of 
drug prescribing and consumption, address the concerns about delayed 
ADRs and examine the increasing costs of drug/therapy [6].
The WHO has devised a set of core drug use indicators, which includes 
prescribing, patient care, and health facility indicators which will 
assist in the implementation of rational prescribing by health care 
workers [7].
Pharmacoeconomics is a new scientific discipline of health economics 
which compares two pharmaceutical drugs/products or therapy. 
It estimates the cost and outcome in terms of efficacy and quality of 
life [8]. These studies provide a guide to ensure that limited resources 
are used in a scientific and competent way to optimize healthcare 
facilities in developing countries [9]. The cost-effective therapy in 
diabetes mellitus will not only lead to adherence to rational prescribing 
but will also increase the patient compliance with fewer drop outs due 
to cost factor. This will lead to less diabetic complications and better 
quality of life thereby improving therapeutic effectiveness.
Hence given above observations, we planned this drug utilization study 
in diabetic patients attending our hospital with a main focus on cost 
analyses. Our main aim was to study the prescription patterns, compare 
the cost of antidiabetic drugs and to suggest the best cost effective 
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therapy in diabetic patients to ensure maximum adherence to therapy 
and decrease morbidity and mortality due to complications.
METHODS
The study was performed prospectively over a period of 6-month 
from June to November 2015. All the data were collected on a 
predesigned case record form from diabetic patients attending the 
medicine outpatient department (OPD). Diabetic patients were 
enrolled in the study after taking written informed consent from 
each patient. Permission was obtained from Institutional Ethics 
Committee.
Patients having diabetes alone, receiving any type of antidiabetic 
medication or with other comorbid conditions were also included in the 
study. Patients having any prior or recent complications due to diabetes 
or were admitted due to it were also included. Only female diabetic 
patients who were pregnant or those patients having inadequate data 
of previous treatment/complications or those patients not willing to 
participate in the study were excluded from the study.
The case record form was designed in such a manner to include all 
demographic characteristics of the patient, disease profile, drug 
profile, and prescription profiles. A copy of the patient’s pharmacy bill 
was also collected from the indoor pharmacy and was analyzed. The 
drug formulation, its individual retail price, manufacturer details, the 
monthly cost borne by the patient was noted down. Further, the cost 
of particular drug which was manufactured by different companies, in 
the same strength and dosage form were evaluated, and the difference 
in maximum and minimum price were calculated. For the drugs whose 
generic names were not written on prescription and price was not 
mentioned in the bill, we used Current Index of Medical Specialties and 
Indian Drug Review Oct-Dec 2015 issues to find the generic names, the 
combinations and their cost.
Percentage variation in cost was calculated using this formula as 
follows:
Percentage cost variation




ost of lowest priced product
Cost of lowest priced product
×100
Statistical analysis
The data were analyzed and mentioned in simple frequencies and 
percentages.
RESULTS
A total of 278 prescriptions were collected over a period of 6-month, 
out of which 262 were fit to be analyzed.
Highest numbers of patients were in the age group 50-60 years 
(39.69%). 16 patients (6.1%) patients were below 40 years age 
group. Out of 262 prescriptions studied, more number were 
males, i.e., 141 (53.82%) and less were females, i.e., 121 (46.18%). 
Maximum patients had diabetes for 6-10 years, i.e., 80 patients 
(30.53%). Fasting blood glucose levels were 126-200 mg/dl in 
a maximum number of patients, i.e., in 165 (62.97%) patients. 
225 patients had comorbidity and the most common comorbid 
condition was metabolic disorder in 87 (33.21%) patients out 
of 225. 115 (43.89%) patients had diabetic complications and 
the most common complication was diabetic neuropathy in 
36 (31.30%) patients. 147 (56.11%) patients had no complications. 
Positive family history of diabetes in either or both the parents was 
observed in 236 (90.07%) patients (Table 1).
Table 1 shows the demographic profile of patients including age groups, 
gender, duration of disease, fasting blood glucose levels, number of 
patients suffering from comorbid conditions, and complications and 
number of patients having family history of diabetes.
Polypharmacy was evident in the study as 176 (67.17%) prescriptions 
had 2-5 drugs. Of the antidiabetic drugs maximum number 
185 (70.61%) had 2-5 drugs and only 67 (25.57%) prescriptions had <2 
antidiabetic drugs. Insulin was used in 37 (14.12%) prescriptions. The 
most common route prescribed was oral in 208 (79.38%) prescriptions. 
Only 111 (42.36%) prescriptions were complete in terms of dose, route, 
strength, frequency, diagnosis, and dosage forms. Among the WHO core 
prescribing indicators the average number of drugs prescribed were 
4.61/prescription. Merely 55 (4.54%) drug names were in generic 
forms. Only 45 (3.72%) were antibiotics and 67 (5.54%) were in 
injectable forms. Drugs on essential drug list (EDL) in prescriptions in 
accordance to the 19th list of 2015 were 526 (43.50%) (Tables 2 and 3).
Table 2 shows the prescription profile including number of drugs 
prescribed, number of single and combination antidiabetic drugs 
and insulin prescribed. It also shows the dosage forms used and 
completeness of prescriptions.
Table 3 shows the WHO core prescribing indicators including average 
drugs prescribed per prescription, drugs prescribed by generic names, 
antibiotics used, injectables used, and drugs used from EDL.
The total number of drugs prescribed in 262 prescriptions was 1209; 
hence, the average number of drugs per prescription are 4.61. Out of 
1209 drugs, 556 (45.98%) were single antidiabetic drugs, 179 (14.81%) 
were a combination of antidiabetic drugs and 37 (3.06%) were insulin. 
Highest prescribed among other drugs were atorvastatin 86 (7.11%), 
aspirin 54 (4.46%), telmisartan 51 (4.22%), antibiotics 45 (3.72%), and 
Table 1: Demographic profile of patients (n=262)
S. No. Variables N (%)






















a. With comorbidity 225 (85.87)
Hypertension alone 76 (33.77)
Hyperlipidemia alone 62 (27.55)
Metabolic disorder 87 (33.21)
b. Without comorbidity 37 (14.12)
6. Complications
a. With complications 115 (43.89)
Diabetic neuropathy 36 (31.30)
Diabetic ketoacidosis 27 (23.47)
Diabetic nephropathy 20 (17.39)
Cardiovascular disease 17 (14.78)
Hypoglycemia 11 (9.56)
Retinopathy 4 (3.47)
b. Without complications 147 (56.11)
7. Family history of diabetes 236 (90.07)
a. One parent 167 (70.76)
b. Both parents 69 (29.23)
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furosemide 40 (3.31%). Rest of the drugs prescribed were enalapril, 
nifedipine, hydrochlorothiazide, rosuvastatin and others including 
vitamins and antioxidants (Table 4).
Table 4 shows the various drugs prescribed – Single or combination 
antidiabetic, insulin, and other drugs according to the comorbid 
condition.
The most common single antidiabetic drug used was metformin 
500 mg in 189 (33.99%) followed by glimepiride 2 mg in 71 (12.76%) 
and least prescribed was repaglinide 1 mg in 8 (1.43%) patients. The 
most common antidiabetic combination used was glimepiride 2 mg 
+ metformin 500 mg in 62 (34.63%) and least used was glipizide 
5 mg + metformin 500 mg in 3 (1.67%) patients. The most common 
insulin preparation used was insulin - soluble 30% + isophane 70% 
in 13 (35.13%) and least common was insulin soluble 50% + insulin 
isophane 50% in 6 (16.21%) patients (Tables 5-7).
Percentage cost difference of single antidiabetic drug ranges from 40.62 
to 633.33, of combination antidiabetics ranges from 40 to 297.22 and 
insulin preparations ranges from 2.81 to 60.63 (Tables 5-7).
Table 5 shows the frequency of single antidiabetics prescribed and their 
percentage cost difference.
Table 6 shows the frequency of combination antidiabetics prescribed 
and their percentage cost difference.
Table 7 shows the frequency of insulin preparations prescribed and 
their percentage cost difference.
The cost of monthly therapy for a diabetic patient as calculated from 
the patient’s pharmacy bill ranged from INR 100 to 3000, maximum 
number of patients being in the cost range INR 100-500 in 148 (56.48%) 
patients followed by cost range INR 500-1000 in 69 (26.33%) patients 
(Table 8).
Table 8 shows the number of patients with their cost of monthly 
antidiabetic therapy.
DISCUSSION
Diabetes, a chronic disease which requires multiple drug therapy, is 
growing in an epidemic proportion. It requires lifestyle modifications 
along with many drugs which apart from controlling diabetes pose 
severe health risks. Since diabetes is a disease of elderly age group, 
there are various other comorbidities; hence, polypharmacy is common 
in such patients (which increases the risk of ADRs, drug interactions, 
and financial burden). Thus, we planned this pharmacoeconomic 
and drug utilization study in diabetic patients to observe the drug 
prescribing pattern, cost effectiveness and evaluate the rationality 
of the prescriptions. Assessing these factors will help improve drug 
usage, generic prescribing and selecting cost-effective drugs/therapy, 
appropriate doses, avoiding irrational drug usage thus decreasing 
the drug-drug interactions, ADRs and expenditure thereby improving 
health outcomes.
A total of 262 prescriptions of diabetic patients were analyzed. 
Demographic analyses show maximum numbers of patients were 
in the age group 50-60 years (39.69%). This result is in consistence 
with the study of Acharya et al. [10]. Furthermore, maximum number 
of patients were in the middle age group from 35 to 64 years which 
was comparable to the study of Das et al. [11]. The predisposition in 
the middle age group has negative socio-economic and psychological 
outcomes which adversely affects the quality of life. 16 patients (6.1%) 
patients were below 40 years age group indicating that Type II diabetes 
is increasing in the younger age group which warrants a strict lifestyle 
modification in those with family history of diabetes from an early 
age. Our study showed males preponderance, i.e., 141 (53.82%) as 
compared to females 121 (46.18%) which is in conformity with another 
previous study of Abdi et al. [12].
Fasting blood glucose levels were 126-200 mg/dl in maximum number 
of patients, i.e., 165 (62.97%) patients. This result is in conformity to 
the study of Assefa et al. [13]. Metabolic disorder was the most common 
comorbid condition associated with diabetes - 87 (33.21%) patients 
followed by hypertension in 76 (33.77%) and hyperlipidemia in 
62 (27.55%) patients. This is in agreement to the study of Acharya et al. 
and Rataboli and Dang [10,14].
In our study most of the patients had diabetes for 6-10 years, found 
in 80 (30.53%) patients followed by 11-15 years in 54 (20.61%) 
patients. Thus, the most common duration of patients having 
diabetes was 6-15 years which was similar to the study of de Pablos-
Velasco et al. [15]. We also found genetic predisposition of diabetes, 
i.e., either or both the parents were suffering from diabetes which was 
observed in 236 (90.07%) patients which is in consistence with other 
studies [16].
Diabetic complications were seen in 115 (43.89%) patients, out 
of which diabetic neuropathy was the most common 36 (31.30%) 
followed by diabetic ketoacidosis in 27 (23.47%) patients, diabetic 
Table 2: Prescription profiles (n=262)
S. No. Variables N (%)
1. Number of drugs prescribed in 
262 prescriptions (polypharmacy)
<2 drugs 56 (21.37)
2-5 drugs 176 (67.17)
>5 drugs 30 (11.45)
2. Total no of antidiabetic drugs prescribed in 
262 prescriptions
<2 drugs 67 (25.57)
2-5 drugs (including combinations) 185 (70.61)
3. Insulin used in 262 prescriptions 37 (14.12)
4. Antidiabetic combinations used in 
262 prescriptions
166 (63.35)
5. Dosage forms prescribed in 262 prescriptions
Oral 208 (79.38)
Injectables 54 (20.61)
6. Complete prescriptions in terms of dose, route, 
strength, frequency, diagnosis and dosage forms
111 (42.36)
Table 3: WHO Core prescribing indicators
S. No. Core prescribing indicators Value (%)
1. Average drug prescribed 4.61
2. Drugs prescribed by generic names 55 (4.54)
3. Antibiotics used 45 (3.72)
4. Injectables used 51 (4.21)
5. Drugs on EDL in prescriptions (19th list 2015) 526 (43.50)
EDL: Essential drug list
Table 4: Drugs prescribed in 262 prescriptions (n=1209)
S. No. Drugs prescribed N (%)
1. Anti-diabetic drugs single 556 (45.98)
2. Anti-diabetic drug combinations 179 (14.81)
3. Insulin 37 (3.06)
4. Enalapril 23 (1.9)
5. Telmisartan 51 (4.22)
6. Nifedipine 31 (2.56)
7. Furosemide 40 (3.31)
8. Hydrochlorothiazide 38 (3.14)
9. Atorvastatin 86 (7.11)
10. Rosuvastatin 17 (1.41)
11. Aspirin 54 (4.46)
12. Antibiotics 45 (3.72)
13. Others (vitamins and antioxidants) 52 (4.3)
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nephropathy in 20 (17.39%) patients, cardiovascular complications in 
17 (14.78%), hypoglycemia in 11 (9.56%), and least was retinopathy 
in 4 (3.47%) patients. This result was dissimilar to the study of Assefa 
et al. held in Ethiopia [13] where diabetic ketoacidosis was the most 
frequent complication reported as there was unaffordability of insulin, 
lack of self-monitoring of glucose levels and low levels of education, all 
of which are much better in India. Diabetic neuropathy was the most 
frequent complication reported here because of indifferent attitude of 
patient who continues to ignore minor symptoms until it becomes a 
major problem.
Our study clearly demonstrated polypharmacy as 176 (67.17%) 
prescriptions had 2-5 drugs. The most common route prescribed was 
oral in 208 (79.38%) prescriptions as it was an OPD based study and 
only insulin was given in the injectable (subcutaneous) form only when 
the blood glucose levels were not being controlled by antidiabetic drugs 
alone. This shows better awareness and adherence of doctors to the 
prescriptions guidelines in diabetes.
The WHO core prescribing indicators showed that average number 
of drugs/prescription is 4.61 which is a high number. Moreover, only 
4.54% drugs were written in their generic names, rest had brand names 
written confirming the role of pharmaceutical companies influencing 
the prescription patterns. Thus, there is a wide gap in knowledge and 
practice of physicians who should be encouraged to prescribe generic 
drugs as it provides consistency in prescriptions and also helps to curtail 
the cost. In our study, 3.72% of patients were prescribed antibiotics 
and 4.21% took the drugs in injectable form. Drugs prescribed from the 
19th EDL 2015 were only 43.5% which shows that physicians prefer to 
use newer drugs in the market.
The most common single antidiabetic prescribed in our study was 
metformin 500 mg in 33.99% of patients followed by glimepiride 2 mg 
in 12.76% and glipizide 5 mg in 11.87% indicating that biguanides and 
sulfonylureas are still the most preferred antidiabetic medications. 
Glimepiride and glipizide were preferred among sulfonylureas as they 
have less incidence of hypoglycemia. These results of our study are 
in conformity to other previous studies of Acharya et al. and Sultana 
et al. [10,17]. Among the newer group gliptans were commonly used 
– vildagliptin and sitagliptin showing the trend of prescribing novel 
Table 5: Single anti‑diabetic drugs used in order of frequency (n=556)
S. No. Drugs Total number of 
patients prescribed (%)
Max price per 
tablet/vial (Rs.)




1. Metformin 500 mg 189 (33.99) 3.4 0.93 265.59
2. Glimepiride 2 mg 71 (12.76) 13.2 1.8 633.33
3. Glipizide 5 mg 66 (11.87) 1.9 0.75 153.33
4. Vildagliptin 50 mg 54 (9.71) 27 19.2 40.62
5. Glimepiride 1 mg 32 (5.75) 7.3 1.4 421.42
6. Metformin 1000 mg 29 (5.21) 4.8 1.75 174.28
7. Sitagliptin 50 mg 24 (4.31) 42.71 29.9 42.84
8. Pioglitazone 30 mg 18 (3.23) 11.2 2 460
9. Voglibose 0.2 mg 17 (3.05) 10.2 1.9 436.84
10. Gliclazide 80 mg 15 (2.69) 7.8 2.9 168.96
11. Glibenclamide 5 mg 12 (2.15) 1 0.36 177.77
12. Acarbose 25 mg 11 (1.97) 7 4.2 66.66
13. Pioglitazone 15 mg 10 (1.79) 7 1.2 483.33
14. Repaglinide 1 mg 8 (1.43) 7.8 4.4 77.27
Table 6: Anti‑diabetic drugs combinations used in order of frequency (n=179)
S. No. Drugs Total number of 
patients prescribed (%)
Max price per 
tablet/vial (Rs.)




1. Glimepiride 2 mg+Metformin 500 mg 62 (34.63) 14.3 3.6 297.22
2. Glimepiride 1 mg+metformin 500 mg 44 (24.58) 8 3.7 116.22
3. Pioglitazone 30 mg+metformin 500 mg 30 (16.75) 12.2 3.2 281.25
4. Sitagliptin 50 mg+metformin 500 mg 18 (10.05) 50 22 127.27
5. Glimepiride 2 mg+metformin 500 
mg+pioglitazone 15 mg
13 (7.26) 16.6 5.5 201.81
6. Voglibose 0.2 mg+metformin 500 mg 9 (5.02) 10 3.9 156.41
7. Glipizide 5 mg+metformin 500 mg 3 (1.67) 1.4 1 40
Table 7: Insulin preparations used in order of frequency (n=37)
S. No. Insulin preparations Total number of patients 
prescribed (%)
Max price per 
tablet/vial (Rs)




1. Insulin - soluble 30%+isophane 70% 13 (35.13) 293 285 2.81
2. Insulin - Glargine 11 (29.72) 763 475 60.63
3. Insulin - NPH 7 (18.91) 239 208 14.9
4. Insulin soluble 50%+insulin isophane 50% 6 (16.21) 169 126 34.12
NPH: Neutral protamine hagedorn
Table 8: Cost of monthly therapy (n=262)
S. No Range N (%)
1. <100 INR 0 (0)
2. 100-500 INR 148 (56.48)
3. 500-1000 INR 69 (26.33)
4. 1000-1500 INR 27 (10.30)
5. 1500-2000 INR 9 (3.43)
6. 2000-2500 INR 7 (2.67)
7. 2500-3000 INR 2 (0.76)
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drugs by the physicians. Insulin was used only in 3.06% patients as 
mostly this study was conducted on OPD patients. Our results greatly 
differ from the study of Johnson et al. where 25.3% patients were 
prescribed insulin [18]. This difference may be due to difference in 
study population, better patient compliance and enhanced patient 
awareness, regular self-monitoring of blood glucose levels so as to have 
a better control of their blood sugar levels, hence a decreased need of 
insulin as an add on to antidiabetic drugs.
A total of 179 antidiabetic combination drugs were used in our study. 
Among them the most commonly used was glimepiride + metformin 
in 106 (59.21%) patients. Our results are in agreement to the study 
of Sivasankari et al. [19] and Das et al. [11]. This drug combination is 
the most rational among antidiabetic drugs as both drugs are acting 
through diverse mechanisms. Sulfonylureas are insulin secretagogues 
and biguanides are insulin sensitizers. Insulin preparations were 
used in 37 (14.12%) patients which mostly consists of soluble 30% + 
isophane 70% in 13 (35.13%) patients. Glargine and NPH or neutral 
protamine hagedorn were used to a lesser extent.
Other than antidiabetic drugs the most commonly used medications 
were atorvastatin 86 (7.11%), aspirin 54 (4.46%), telmisartan 
51 (4.22%), antibiotics 45 (3.72%), and furosemide 40 (3.31%). 
The use of statins, aspirin, ARBs, and diuretics suggest that 
hypercholesterolemia, hypertension, and hence, metabolic syndrome 
that includes a combination of all these diseases was common in these 
patients. Antibiotic use was found in patients suffering from secondary 
infections due to diabetic complications.
On evaluating the pharmacy bill of patients, we found that the monthly 
cost of antidiabetic therapy in most of the patients were in the range 
of 100-500 INR. Our findings were similar to the study of Acharya 
et al. [10]. Since diabetes is a chronic disease, sometimes even requiring 
life-long therapy, the high prescription cost can be a burden especially 
in middle-income households and may even lead to non-compliance.
We calculated the percentage cost difference of antidiabetic drugs, 
combinations, and insulin prescribed. Glimepiride had the maximum 
percentage cost difference, i.e. 633.33 and gliptans had the least 
percentage cost difference. These results demonstrate that glimepiride 
has more brands available in the market as compared to other drugs, 
thus the physicians should prescribe the most economical brand in 
the market to reduce the total cost of drug therapy. The findings of our 
study were corroborated with the study of Jadhav and Adhav [20] who 
also showed that glimepiride had the maximum cost variation. Gliptans 
had the least percentage cost difference as these are newer drugs and 
very few brands are available in the market. Among the combinations 
glimepiride + metformin had the maximum percentage cost difference 
and glipizide + metformin had the least percentage cost difference 
illustrating more number of brands for glimepiride + metformin. 
Insulin preparations also show lower percentage cost differences as 
few brands are available in the market are all are almost equally priced. 
Hence, cost factor in antidiabetic therapy is important for patient 
compliance and the clinicians should wisely chose the cheapest brand 
or the generic antidiabetic drugs for reducing the economic burden and 
improving the health status.
CONCLUSION
In our study, we found that average number of drugs per prescription 
was high indicating toward polypharmacy. The single most commonly 
prescribed drug was metformin and the most common combination 
used was glimepiride 2 mg + metformin 500 mg. In most patients, the 
cost of monthly antidiabetic therapy was relatively high, and hence, 
there is need of rational prescribing including more generic drugs so 
that the therapy is economical for the patient.
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